|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2010-5-24
|
|
pubmed:abstractText |
Over-expression of multidrug resistance (MDR) proteins PGP and BCRP has a negative prognostic impact in acute myeloid leukemia (AML) patients. Inclusion of fludarabine in induction chemotherapy increases remission rate in PGP over-expressing cases. We investigated the role of BCRP in 138 adult AML patients receiving induction therapy with fludarabine. None of the MDR-related proteins influenced complete remission attainment. Conversely, high levels of BCRP significantly affected disease-free survival, as higher relapse rates (48.5% vs 28.5%) and earlier relapse occurred in BCRP+ patients. Also overall survival was affected by BCRP positivity, and survival significantly worsened in case of concomitant PGP and BCRP over-expression.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
1873-5835
|
|
pubmed:author |
pubmed-author:CavallinMargheritaM,
pubmed-author:DamanteGiuseppeG,
pubmed-author:DamianiDanielaD,
pubmed-author:FabbroDoraD,
pubmed-author:FaninRenatoR,
pubmed-author:GerominAntonellaA,
pubmed-author:MalagolaMicheleM,
pubmed-author:MicheluttiAngelaA,
pubmed-author:PiantaAnnalisaA,
pubmed-author:RussoDomenicoD,
pubmed-author:TiribelliMarioM
|
|
pubmed:copyrightInfo |
Copyright 2010 Elsevier Ltd. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
34
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
942-5
|
|
pubmed:meshHeading |
pubmed-meshheading:20122734-ATP-Binding Cassette Transporters,
pubmed-meshheading:20122734-Acute Disease,
pubmed-meshheading:20122734-Adolescent,
pubmed-meshheading:20122734-Adult,
pubmed-meshheading:20122734-Aged,
pubmed-meshheading:20122734-Aged, 80 and over,
pubmed-meshheading:20122734-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:20122734-Disease-Free Survival,
pubmed-meshheading:20122734-Drug Resistance, Neoplasm,
pubmed-meshheading:20122734-Female,
pubmed-meshheading:20122734-Gene Expression Regulation, Leukemic,
pubmed-meshheading:20122734-Humans,
pubmed-meshheading:20122734-Leukemia, Myeloid,
pubmed-meshheading:20122734-Male,
pubmed-meshheading:20122734-Middle Aged,
pubmed-meshheading:20122734-Multidrug Resistance-Associated Proteins,
pubmed-meshheading:20122734-Neoplasm Proteins,
pubmed-meshheading:20122734-P-Glycoprotein,
pubmed-meshheading:20122734-Remission Induction,
pubmed-meshheading:20122734-Vidarabine,
pubmed-meshheading:20122734-Young Adult
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Fludarabine-based induction therapy does not overcome the negative effect of ABCG2 (BCRP) over-expression in adult acute myeloid leukemia patients.
|
|
pubmed:affiliation |
Clinica Ematologica e Centro Trapianti e Terapie Cellulari C. Melzi, Azienda Ospedaliero-Universitaria di Udine, Dipartimento di Ricerche Mediche e Morfologiche, Università di Udine, Udine, Italy. daniela.damiani@uniud.it
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
